Circulating fibronectin controls tumor growth

Neoplasia (United States)

Volumn 15, Issue 8, 2013, Pages 925-938

  von Au, Anja ^a,b   Vasel, Matthaeus ^a,b   Kraft, Sabrina ^a,b   Sens, Carla ^a,b   Hackl, Norman ^a,b   Marx, Alexander ^c   Stroebel, Philipp ^c   Hennenlotter, Jörg ^d   Todenhöfer, Tilman ^d   Stenzl, Arnulf ^d   Schott, Sarah ^b   Sinn, Hans Peter ^b   Wetterwald, Antoinette ^e   Bermejo, Justo Lorenzo ^b   Cecchini, Marco G ^e   Nakchbandi, Inaam A ^a,b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DNA DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PERICYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; RNA ANALYSIS; TUMOR BIOPSY; TUMOR GROWTH;

EID: 84881053268     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13762     Document Type: Article

References (50)

1. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et al. (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891-906.
2. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey R. J, Manova-Todorova K, Brogi E, and Massague J (2011). Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 17, 867-874.
3. Manabe R, Ohe N, and Sekiguchi K (1999). Alternatively spliced EDA segment regulates fibronectin-dependent cell cycle progression and mitogenic signal transduction. J Biol Chem 274, 5919-5924.
4. Ohnishi T, Hiraga S, Izumoto S, Matsumura H, Kanemura Y, Arita N, and Hayakawa T (1998). Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin Exp Metastasis 16, 729-741.
5. Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, Cronberg T., Isshiki A, Erickson HP, and Fassler R (2001). Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nat Med 7, 324-330.
6. Moursi AM, Damsky CH, Lull J, Zimmerman D, Doty SB, Aota S, and Globus RK (1996). Fibronectin regulates calvarial osteoblast differentiation. J Cell Sci 109(pt 6), 1369-1380.
7. Johansson S, Svineng G, Wennerberg K, Armulik A, and Lohikangas L (1997). Fibronectin-integrin interactions. Front Biosci 2, d126-d146.
8. Sottile J and Hocking DC (2002). Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol Biol Cell 13, 3546-3559.
9. Goerges AL and Nugent MA (2004). pH regulates vascular endothelial growth factor binding to fibronectin: a mechanism for control of extracellular matrix storage and release. J Biol Chem 279, 2307-2315.
10. Bentmann A, Kawelke N, Moss D, Zentgraf H, Bala Y, Berger I, Gasser JA, and Nakchbandi I. A (2010). Circulating fibronectin affects bone matrix, whereas osteoblast fibronectin modulates osteoblast function. J Bone Miner Res 25, 706-715.
11. Malik G, Knowles LM, Dhir R, Xu S, Yang S, Ruoslahti E, and Pilch J (2010). Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res 70, 4327-4334.
12. Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpe S, Van Marck E, Vermeulen P. B, and Dirix LY (2006). Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 94, 672-680.
13. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, and Vessella RL (2009). Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 15, 677-683.
14. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel L. R, Ying C, Ziegler AM, et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121, 1298-1312.
15. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820-827.
16. Segre JA, Nemhauser JL, Taylor BA, Nadeau JH, and Lander ES (1995). Positional cloning of the nude locus: genetic, physical, and transcription maps of the region and mutations in the mouse and rat. Genomics 28, 549-559.
17. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G, and Arnold B (2001). Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30, 36-44.
18. Kawelke N, Bentmann A, Hackl N, Hager HD, Feick P, Geursen A, Singer MV, and Nakchbandi IA (2008). Isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J Bone Miner Res 23, 1278-1286.
19. Hackl NJ, Bersch C, Feick P, Antoni C, Franke A, Singer MV, and Nakchbandi IA (2010). Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol 45, 349-356.
20. Kawelke N, Vasel M, Sens C, von Au A, Dooley S, and Nakchbandi IA (2011). Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to active TGF-β. PLoS One 6, e28181.
21. Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang J., Mehra R, Keller ET, et al. (2008). An in vivo mouse model for human prostate cancer metastasis. Neoplasia 10, 371-380.
22. Wetterwald A, van der Pluijm G, Que I, Sijmons B, Buijs J, Karperien M, Lowik C. W, Gautschi E, Thalmann GN, and Cecchini MG (2002). Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol 160, 1143-1153.
23. Dong QG, Bernasconi S, Lostaglio S, De Calmanovici RW, Martin-Padura I, Breviario F., Garlanda C, Ramponi S, Mantovani A, and Vecchi A (1997). A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. Arterioscler Thromb Vasc Biol 17, 1599-1604.
24. Allport JR and Weissleder R (2003). Murine Lewis lung carcinoma-derived endothelium expresses markers of endothelial activation and requires tumorspecific extracellular matrix in vitro. Neoplasia 5, 205-217.
25. Zhou X, Rowe RG, Hiraoka N, George JP, Wirtz D, Mosher DF, Virtanen I, Chernousov M. A, and Weiss SJ (2008). Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. Genes Dev 22, 1231-1243.
26. Mitchell TS, Bradley J, Robinson GS, Shima DT, and Ng YS (2008). RGS5 expression is a quantitative measure of pericyte coverage of blood vessels. Angiogenesis 11, 141-151.
27. Muller WA, Ratti CM, McDonnell SL, and Cohn ZA (1989). A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp Med 170, 399-414.
28. Stan RV, Kubitza M, and Palade GE (1999). PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. Proc Natl Acad Sci USA 96, 13203-13207.
29. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I, Tagliafico E, Ferrari S, Robey PG, Riminucci M, et al. (2007). Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131, 324-336.
30. Stratman AN, Malotte KM, Mahan RD, Davis MJ, and Davis GE (2009). Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood 114, 5091-5101.
31. Williams CM, Engler AJ, Slone RD, Galante LL, and Schwarzbauer JE (2008). Fibronectin expression modulates mammary epithelial cell proliferation during acinar differentiation. Cancer Res 68, 3185-3192.
32. Nicosia RF, Bonanno E, and Smith M (1993). Fibronectin promotes the elongation of microvessels during angiogenesis in vitro. J Cell Physiol 154, 654-661.
33. Han SW and Roman J (2006). Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: pro-oncogenic effects mediated by PI3-kinase and NF-κB. Oncogene 25, 4341-4349.
34. Veevers-Lowe J, Ball SG, Shuttleworth A, and Kielty CM (2011). Mesenchymal stem cell migration is regulated by fibronectin through α5β1-integrin-mediated activation of PDGFR-β and potentiation of growth factor signals. J Cell Sci 124, 1288-1300.
35. Wijelath ES, Rahman S, Namekata M, Murray J, Nishimura T, Mostafavi-Pour Z, Patel Y, Suda Y, Humphries MJ, and Sobel M (2006). Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 99, 853-860.
36. Miyamoto S, Teramoto H, Gutkind JS, and Yamada KM (1996). Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J Cell Biol 135, 1633-1642.
37. Cabon L, Galan-Malo P, Bouharrour A, Delavallee L, Brunelle-Navas MN, Lorenzo H. K, Gross A, and Susin SA (2011). BID regulates AIF-mediated caspaseindependent necroptosis by promoting BAX activation. Cell Death Differ 19, 245-256.
38. Zhang Z, Vuori K, Reed JC, and Ruoslahti E (1995). The α5β1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA 92, 6161-6165.
39. Braet F and Wisse E (2002). Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 1, 1.
40. Risau W and Lemmon V (1988). Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol 125, 441-450.
41. McKeown-Longo PJ and Mosher DF (1985). Interaction of the 70,000-mol-wt amino-terminal fragment of fibronectin with the matrix-assembly receptor of fibroblasts. J Cell Biol 100, 364-374.
42. Rangdaeng S and Truong LD (1991). Comparative immunohistochemical staining for desmin and muscle-specific actin. A study of 576 cases. Am J Clin Pathol 96, 32-45.
43. Tallquist MD, French WJ, and Soriano P (2003). Additive effects of PDGF receptor β signaling pathways in vascular smooth muscle cell development. PLoS Biol 1, E52.
44. George EL, Baldwin HS, and Hynes RO (1997). Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 90, 3073-3081.
45. Astrof S, Crowley D, George EL, Fukuda T, Sekiguchi K, Hanahan D, and Hynes R. O (2004). Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol Cell Biol 24, 8662-8670.
46. Palumbo A, Hauler F, Dziunycz P, Schwager K, Soltermann A, Pretto F, Alonso C, Hofbauer GF, Boyle RW, and Neri D (2011). A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer 104, 1106-1115.
47. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rosli C, Borsi L, and Neri D (2008). A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122, 2405-2413.
48. Astrof S, Crowley D, and HynesRO(2007). Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin. Dev Biol 311, 11-24.
49. Carmeliet P and Jain RK (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307.
50. Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, and Park C (2007). Increased β1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67, 659-664.